Candidiasis and other fungal infection references

Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351:1391–1402.

Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol. 2005;43:235–243.

Vazquez JA, Dembry LM, Sanchez V, et al. Nosocomial Candida glabrata colonization: an epidemiologic study. J Clin Microbiol. 1998;36:421–426.

Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev. 1996;9:499–511.

Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358–4366.

Mora-Duarte J, Betts R, Rotstein C, et al, for the Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020–2029.

Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med. 2002;113:294–299.

Drugs@FDA [U.S. Food and Drug Administration website]. Available at: http://www.accessdata.fda.gov/scripts/cder/
drugsatfda/index.cfm?fuseaction=
Search.Label_ApprovalHistory#apphist. Accessed July 15, 2005.

Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:161–189.

10.

Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999;29:239–244.

11.

Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ, and the SENTRY Participants Group. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol. 2002;40:852–856.

12.

Nguyen MH, Peacock JE Jr, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996;100:617–623.

13.

Berrouane YF, Herwaldt LA, Pfaller MA. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J Clin Microbiol. 1999;37:531–537.

14.

Loeffler J, Stevens DA. Antifungal drug resistance. Clin Infect Dis. 2003;36(suppl 1):S31–S41.

15.

The Hospital Antifungal Market Guide and The Hospital Anti-Infective Market Guide. United States Editions 2001–2005. AMR/Arlington Medical Resources, Inc, Malvern, Pa.

16.

Diflucan [package insert]. New York, NY: Pfizer Inc; 2004.

17.

Vfend [package insert]. New York, NY: Pfizer Inc; 2005.

18.

AmBisome [package insert]. Deerfield, Ill: Astellas Pharma US Inc; 2005.

19.

Gubbins PO, Anaissie E. Overview of antifungal agents. Infectious Disease Special Edition. 2002;5:65–70.

20.

Pfaller MA, Diekema DJ for the International Fungal Surveillance Participant Group. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect. 2004;10(suppl 1):11–23.

21.

Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J. The direct cost and incidence of systemic fungal infections. Value Health. 2002;5:26–34.

22.

Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–317.

23.

Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640–3645.

24.

Mycamine [package insert]. Deerfield, Ill: Astellas Pharma US Inc; 2005.

25.

Eraxis [package insert]. New York, NY: Pfizer Inc; 2006.

26.

Amphocin [package insert]. New York, NY: Pfizer Inc; 2003.

27.

Abelcet [package insert]. Bridgewater, NJ: Enzon Pharmaceuticals Inc; 2002.

28.

Amphotec [package insert]. Brisbane, Calif: InterMune Inc; 2001.

29.

Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother. 1997;41:2326–2332.

When CANCIDAS is co-administered to pediatric patients with inducers of drug clearance, such as rifampin, efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, a dose of 70 mg/m² daily (not to exceed an actual daily dose of 70 mg) should be considered.

The most common adverse reactions in adult patients treated with CANCIDAS (≥10%), regardless of causality, are: diarrhea, pyrexia, chills, ALT/AST increase, blood alkaline phosphatase increase, and decrease of blood potassium.

The most common adverse reactions in pediatric patients treated with CANCIDAS, regardless of causality, were pyrexia (29.2%), blood potassium decreased (15.2%), diarrhea (14%), increased aspartate aminotransferase (11.7%), rash (11.7%), increased alanine aminotransferase (11.1%), hypotension (11.1%), and chills (11.1%).

There is no clinical experience in adult patients with severe hepatic insufficiency (Child-Pugh score >9) and in pediatric patients with any degree of hepatic insufficiency.

Administer by slow intravenous infusion (IV) over approximately 1 hour. Not for IV bolus administration.

Before prescribing CANCIDAS, please read the Prescribing Information.